Ahmed Fayed1, Rasmia Elgohary2, Mary Fawzy3. 1. Nephrology Unit, Internal Medicine Department, Kasr Al-Ainy School of Medicine, Cairo University, Cairo, Egypt. 2. Rheumatology & Clinical Immunology Unit, Internal Medicine Department, Kasr Al-Ainy School of Medicine, Cairo University, Al-Saray St., El-Maniel, Cairo, 11562, Egypt. rasmiaelgohary@kasralainy.edu.eg. 3. Rheumatology & Clinical Immunology Unit, Internal Medicine Department, Kasr Al-Ainy School of Medicine, Cairo University, Al-Saray St., El-Maniel, Cairo, 11562, Egypt.
Abstract
OBJECTIVE: Sclerostin is an osteocyte-derived glycoprotein which inhibits the canonical Wnt pathway essential for osteoblastic activity decreasing bone formation. Its potential role in rheumatoid arthritis (RA) pathogenesis was highlighted by experimental studies. Here we measured the serum sclerostin in RA patients and evaluated its relationship with disease activity and damage. METHODS: One hundred RA patients and 80 age and sex-matched healthy controls were enrolled in the study. Bone biomarkers were evaluated for all participants including total calcium, phosphorus, alkaline phosphatase, 25-hydroxy vitamin D, and intact parathyroid hormone, in addition to fibroblast growth factor-23 (FGF23) and serum sclerostin. For RA patients, carotid intima-media thickness, brachial artery flow dilatation, and musculoskeletal ultrasonography using ultrasonography-7 joint score were done, and DAS28-ESR was calculated. RESULTS: Median serum sclerostin in our patients was 186.5 ± 22.7 pg/ml which was significantly higher than in controls 60.6 ± 7.1 pg/ml (p < 0.002). Serum sclerostin showed no correlation with disease activity, bone erosions, carotid intima-media thickness, brachial flow dilatation, and the examined bone biomarkers. However, it had a strong correlation with FGF23 (r coefficient 0.988, p < 0.000). CONCLUSION: Although serum sclerostin was elevated in RA patients, it could not be used as a prognostic marker for disease activity, bone erosions or atherosclerosis.Key Points• Serum sclerostin may not reflect changes in the joint microenvironment being not correlated with ultrasonography-detected synovitis or erosions.• Serum sclerostin was elevated in RA patients irrespective to their age or gender.• The positive correlation with FGF23 may provide evidence for sclerostin contribution in bone demineralization in RA patients.
OBJECTIVE:Sclerostin is an osteocyte-derived glycoprotein which inhibits the canonical Wnt pathway essential for osteoblastic activity decreasing bone formation. Its potential role in rheumatoid arthritis (RA) pathogenesis was highlighted by experimental studies. Here we measured the serum sclerostin in RApatients and evaluated its relationship with disease activity and damage. METHODS: One hundred RApatients and 80 age and sex-matched healthy controls were enrolled in the study. Bone biomarkers were evaluated for all participants including total calcium, phosphorus, alkaline phosphatase, 25-hydroxy vitamin D, and intact parathyroid hormone, in addition to fibroblast growth factor-23 (FGF23) and serum sclerostin. For RApatients, carotid intima-media thickness, brachial artery flow dilatation, and musculoskeletal ultrasonography using ultrasonography-7 joint score were done, and DAS28-ESR was calculated. RESULTS: Median serum sclerostin in our patients was 186.5 ± 22.7 pg/ml which was significantly higher than in controls 60.6 ± 7.1 pg/ml (p < 0.002). Serum sclerostin showed no correlation with disease activity, bone erosions, carotid intima-media thickness, brachial flow dilatation, and the examined bone biomarkers. However, it had a strong correlation with FGF23 (r coefficient 0.988, p < 0.000). CONCLUSION: Although serum sclerostin was elevated in RApatients, it could not be used as a prognostic marker for disease activity, bone erosions or atherosclerosis.Key Points• Serum sclerostin may not reflect changes in the joint microenvironment being not correlated with ultrasonography-detected synovitis or erosions.• Serum sclerostin was elevated in RApatients irrespective to their age or gender.• The positive correlation with FGF23 may provide evidence for sclerostin contribution in bone demineralization in RApatients.
Authors: Vincent M Brandenburg; Patrick D'Haese; Annika Deck; Djalila Mekahli; Björn Meijers; Ellen Neven; Pieter Evenepoel Journal: Pediatr Nephrol Date: 2015-03-04 Impact factor: 3.714
Authors: Cristina Vincent; David M Findlay; Katie J Welldon; Asiri R Wijenayaka; Timothy S Zheng; David R Haynes; Nicola L Fazzalari; Andreas Evdokiou; Gerald J Atkins Journal: J Bone Miner Res Date: 2009-08 Impact factor: 6.741
Authors: Zachary C Ryan; Hemamalini Ketha; Melissa S McNulty; Meghan McGee-Lawrence; Theodore A Craig; Joseph P Grande; Jennifer J Westendorf; Ravinder J Singh; Rajiv Kumar Journal: Proc Natl Acad Sci U S A Date: 2013-03-25 Impact factor: 11.205
Authors: Churl Hyun Im; Na Ri Kim; Jong Wan Kang; Ji Hun Kim; Jin Young Kang; Gi Bum Bae; Eon Jeong Nam; Young Mo Kang Journal: Rheumatology (Oxford) Date: 2014-10-09 Impact factor: 7.580
Authors: Juan Rafael Muñoz-Castañeda; Cristian Rodelo-Haad; Maria Victoria Pendon-Ruiz de Mier; Alejandro Martin-Malo; Rafael Santamaria; Mariano Rodriguez Journal: Toxins (Basel) Date: 2020-03-16 Impact factor: 4.546